Recente en toekomstige behandelingen bij covid-19

Marloes Dankers; H. Marjorie J.M.G. Nelissen-Vrancken; Marjolein Y. Berger; Marc J.M. Bonten; Joop M.A. van Gerven; Peter W.A. Kunst; Majon Muller; Marcel G.M. Olde Rikkert; Frits R. Rosendaal

Recente en toekomstige behandelingen bij covid-19

Translated title of the contribution: Current and future therapeutic options for COVID-19

Marloes Dankers, H. Marjorie J.M.G. Nelissen-Vrancken, Marjolein Y. Berger, Marc J.M. Bonten, Joop M.A. van Gerven, Peter W.A. Kunst, Majon Muller, Marcel G.M. Olde Rikkert, Frits R. Rosendaal

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

Translated title of the contribution	Current and future therapeutic options for COVID-19
Original language	Dutch
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	166
Publication status	Published - 21 Jul 2022

Cite this

@article{fba0627be4b44daf8b3bcb3496a1e868,

title = "Recente en toekomstige behandelingen bij covid-19",

abstract = "The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.",

author = "Marloes Dankers and Nelissen-Vrancken, {H. Marjorie J.M.G.} and Berger, {Marjolein Y.} and Bonten, {Marc J.M.} and {van Gerven}, {Joop M.A.} and Kunst, {Peter W.A.} and Majon Muller and {Olde Rikkert}, {Marcel G.M.} and Rosendaal, {Frits R.}",

year = "2022",

month = jul,

day = "21",

language = "Dutch",

volume = "166",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

}

TY - JOUR

T1 - Recente en toekomstige behandelingen bij covid-19

AU - Dankers, Marloes

AU - Nelissen-Vrancken, H. Marjorie J.M.G.

AU - Berger, Marjolein Y.

AU - Bonten, Marc J.M.

AU - van Gerven, Joop M.A.

AU - Kunst, Peter W.A.

AU - Muller, Majon

AU - Olde Rikkert, Marcel G.M.

AU - Rosendaal, Frits R.

PY - 2022/7/21

Y1 - 2022/7/21

N2 - The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

AB - The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85136839545&partnerID=8YFLogxK

M3 - Article

C2 - 36036702

SN - 0028-2162

VL - 166

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

ER -

Recente en toekomstige behandelingen bij covid-19

Abstract

Other files and links

Cite this